Evidence map›Paper›PMID 42581211›Full record

ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2026

Nitrogen-doped carbon nanodots as a biocompatible FRET donor for caspase-3 detection and chemotherapy response evaluation in osteosarcoma cell lysates.

Qingwei Wang, Zheng Xu, Deluo Wu, Yao Zhang, Jian'an Li, Fuyuan Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qingwei WangDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China.
Zheng XuDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China.
Deluo WuDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China.
Yao ZhangDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China.
Jian'an LiDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China.
Fuyuan MaDepartment of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province, China. mfy18852715529@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a highly aggressive bone malignancy requiring precise tools for early diagnosis and effective evaluation of chemotherapy efficacy. Here, we report an "off-on" fluorescent nanosensor based on nitrogen-doped carbon nanodots (N-CNDs) for the sensitive and selective detection of caspase-3 activity, a key apoptosis executor. The sensor is constructed by conjugating carboxyl-functionalized N-CNDs with a BHQ1-labeled peptide substrate containing the caspase-3-specific DEVD cleavage motif. In the absence of caspase-3, fluorescence is quenched via FRET. Upon caspase-3 activation, the peptide is cleaved, releasing BHQ1 and restoring fluorescence. The nanosensor exhibits high sensitivity (detection limit of 0.0106 U/mL), excellent selectivity, and robust performance in complex biological media. As a proof-of-concept application, it detects elevated caspase-3 activity in osteosarcoma cell lysates (MG-63) compared to normal osteoblast lysates (hFOB1.19) and enables quantitative, dose-dependent assessment of apoptosis induced by cisplatin and doxorubicin directly in cancer cell lysates. With its current format, this cell-lysate-based platform provides a practical and sensitive tool for preclinical drug screening and rapid comparison of chemotherapeutic potency, while laying a foundation for future adaptation toward live-cell and in vivo imaging applications.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsBone NeoplasmsCaspase 3Fluorescence Resonance Energy TransferNitrogenOsteosarcomaApoptosisCarbonCarbon Quantum DotsCell Line, TumorCisplatinDoxorubicinFluorescent Chemosensor CompoundsHumansAntineoplastic AgentsBiocompatible MaterialsCarbonCaspase 3CisplatinDoxorubicinFluorescent Chemosensor CompoundsNitrogenApoptosisCaspase-3Chemotherapy evaluationFluorescent nanosensorNitrogen-doped carbon nanodotsOsteosarcoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.